IPO - Guardian Pharmacy Services, Inc.

Form Type: 424B4

Filing Date: 2025-05-23

Corporate Action: Ipo

Type: New

Accession Number: 000119312525125837

Filing Summary: Guardian Pharmacy Services, Inc. is offering 1,440,447 shares of Class A common stock, with selling stockholders, including the founders, offering an additional 6,059,553 shares. The company will not receive proceeds from the selling stockholders. The primary use of net proceeds is for a synthetic secondary transaction to purchase outstanding shares of Class A common stock. The company is categorized as an emerging growth company and is compliant with reduced public company reporting requirements. As of March 31, 2025, Guardian operates 51 pharmacies and serves approximately 189,000 residents in 38 states, focusing primarily on longer-term care facilities. The last reported price of the Class A common stock was $22.58 per share on May 22, 2025. Key financial figures include 2024 revenue of $1.228 billion and an increase in net income from $37.7 million in 2023 to a loss of $71 million in 2024. The IPO completed on September 27, 2024, involved 9,200,000 shares at $14.00 each, generating net proceeds of $119.8 million for the company. The document outlines risks associated with investing in the company's stock and emphasizes the benefits and management of drug regimens in long-term care facilities.

Form Type: S-1

Filing Date: 2025-05-20

Corporate Action: Ipo

Type: New

Accession Number: 000119312525123149

Filing Summary: Guardian Pharmacy Services, Inc. is making a public offering of 1,440,447 shares of its Class A common stock, while selling stockholders, primarily the company's founders, are offering an additional 6,059,553 shares. The primary goal of the offering is to facilitate a synthetic secondary transaction to purchase outstanding shares of Class A common stock that were issued upon the conversion of Class B common stock connected to the company's Corporate Reorganization. The public offering price has been indicated at $26.52 per share. Following the offering, the founders are projected to maintain control over approximately 57% of the voting power associated with shares eligible for director elections. The company, defined as an emerging growth entity, plans to utilize the proceeds primarily for its Corporate Reorganization and operational requirements. The offering seeks to support Guardian's continued operations in the healthcare sector by providing critical pharmacy services to long-term care facilities and establishing a foothold in the market for Class A common stock on the NYSE.

Form Type: 10-Q

Filing Date: 2025-05-12

Corporate Action: Ipo

Type: New

Accession Number: 000119312525117801

Filing Summary: Guardian Pharmacy Services, Inc. details its quarterly financial results for the period ended March 31, 2025, reporting a net income of $9,273,000, significantly increased from $7,095,000 in the same period of the previous year. The company had revenue growth, with total revenues reaching $329,308,000, compared to $275,410,000 before. This quarterly report marks the period following the company's initial public offering (IPO) and related Corporate Reorganization that occurred on September 27, 2024, during which all preferred units were converted to common units and membership interests were adjusted accordingly. The corporate reorganization was crucial for preparing the business transition to a publicly traded company, and it included a merger process which converted common units into Class B common stock, alongside cash payments to unit holders. The company now has 22,719,946 shares of Class A common stock and 40,566,696 shares of Class B common stock outstanding. Guardian Pharmacy continues to focus on providing pharmacy services to long-term care facilities, emphasizing individualized care and clinical outcomes to reduce patient costs.

Form Type: DRS

Filing Date: 2025-04-08

Corporate Action: Ipo

Type: New

Accession Number: 000095012325003388

Filing Summary: Guardian Pharmacy Services, Inc. filed a confidential registration statement with the SEC for a proposed public offering of its Class A common stock. This offering aims to allow selling stockholders, including executive officers and certain directors, to sell shares without the company receiving proceeds. The company aims to use the net proceeds from this offering to engage in a Synthetic Secondary transaction to buy outstanding shares of Class A common stock. The document outlines the structure of their stock classes and emphasizes their emergence as a differentiated pharmacy service provider focused on serving residents of long-term health care facilities. It highlights the company's impressive market share, revenue achievements, and commitment to employee ownership while unveiling their growth strategy centered on expanding market presence and forging new partnerships.